CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
20. November 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
12. November 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11. November 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30. August 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
18. Juni 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06. Juni 2024 12:14 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
24. Mai 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03. Mai 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26. April 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24. April 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024